公开(公告)号：US12275797B2

公开(公告)日：2025-04-15

申请号：US17253276

申请日：2019-06-24

Applicant: GENMAB HOLDING B.V.

Inventor： Simone Oostindie ,  Frank Beurskens ,  Ronald Taylor ,  Margaret Lindorfer ,  Hilma Van Der Horst ,  Martine E. D. Chamuleau ,  Tuna Mutis ,  Paul Parren ,  Esther Breij

IPC: A61K39/395 ,  A61K45/06 ,  C07K16/28

Abstract: The present invention relates to anti-CD37antibodies having an Fc-Fc interaction enhancing substitution in the Fc-region of a human IgG, for use as a medicament in combination with anti-CD20 antibodies having an Fc-Fc interaction enhancing substitution in the Fc-region of a human IgG. The invention also relates to a novel composition of anti-CD37 antibodies having an Fc-Fc 5 interaction enhancing substitution and anti-CD20 antibodies having an Fc-Fc interaction enhancing substitution. In particular, the invention relates to compositions wherein the anti-CD37 antibody binds human CD37 and the anti-CD20 antibody binds human CD20. The invention also relates to compositions where the composition is a pharmaceutical composition and the use of such compositions in treatment of cancer and other diseases.

公开(公告)号：US20240392032A1

公开(公告)日：2024-11-28

申请号：US18617483

申请日：2024-03-26

Applicant: Genmab A/S

Inventor： David SATIJN ,  Esther C.W. Breij ,  Bart E.C.G. De Goeij ,  Kristel Kemper ,  Patrick Engelberts ,  Edward N. Van Den Brink ,  Rik Rademaker ,  Dennis Verzijl ,  Sjeng Horbach ,  Paul Parren

IPC: C07K16/30 ,  A61K39/00 ,  A61K47/68 ,  A61P35/00 ,  C12N15/79

Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US12049512B2

公开(公告)日：2024-07-30

申请号：US16921154

申请日：2020-07-06

Applicant: GENMAB B.V.

Inventor： Paul Parren ,  Frank Beurskens ,  Rob N. De Jong ,  Aran Frank Labrijn ,  Janine Schuurman

IPC: C07K16/00 ,  C07K16/28 ,  C07K16/36 ,  C12P21/08 ,  A61K39/00 ,  C07K1/00

CPC classification number: C07K16/2896 ,  C07K16/00 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/36 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/77 ,  C07K2317/90 ,  C07K2317/92

Abstract: Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.

公开(公告)号：US20230374131A1

公开(公告)日：2023-11-23

申请号：US18109708

申请日：2023-02-14

Applicant: Genmab A/s

Inventor： Edward Norbert VAN DEN BRINK ,  Joost J. Neijssen ,  Aran Frank Labrijn ,  Joyce Meesters ,  Janine Schuurman ,  Isil Altintas ,  Paul Parren ,  Rik Rademaker

IPC: C07K16/28 ,  C07K16/32 ,  C07K16/10 ,  C07K16/42 ,  G01N33/68

CPC classification number: C07K16/2809 ,  C07K16/2887 ,  C07K16/32 ,  C07K16/1063 ,  C07K16/2863 ,  C07K16/2896 ,  C07K16/4241 ,  G01N33/6872 ,  A61K2039/505

Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

公开(公告)号：US11814411B2

公开(公告)日：2023-11-14

申请号：US17144591

申请日：2021-01-08

Applicant: BIONTECH SE ,  GENMAB A/S

Inventor： Ugur Sahin ,  Friederike Gieseke ,  Isil Altintas ,  David Satijn ,  Paul Parren

IPC: C07K16/28

CPC classification number: C07K16/2878 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/92

Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.

公开(公告)号：US11180572B2

公开(公告)日：2021-11-23

申请号：US14413178

申请日：2013-07-05

Applicant: GENMAB B.V.

Inventor： Rob N. De Jong ,  Frank Beurskens ,  Paul Parren ,  Aran Frank Labrijn ,  Janine Schuurman ,  Arjen Vlug ,  Sandra Verploegen

IPC: C07K16/00 ,  A61K39/395 ,  C07K16/28 ,  C07K16/30 ,  C07K16/40 ,  C07K16/32 ,  C07K16/10 ,  C07K16/36 ,  C07K16/12 ,  A61K39/00

Abstract: The present invention relates to dimeric proteins comprising amino acids at three different positions which are different from those present in a human IgG1. Six of said dimeric proteins are capable of forming a hexameric structure in solution.

公开(公告)号：US11046771B2

公开(公告)日：2021-06-29

申请号：US15832366

申请日：2017-12-05

Applicant: GENMAB A/S

Inventor： Bart De Goeij ,  Simone De Haij ,  Thilo Riedl ,  Rene Hoet ,  Ole Baadsgaard ,  Jan Van De Winkel ,  David Satijn ,  Paul Parren ,  Aran Frank Labrijn ,  Joyce Meesters ,  Janine Schuurman ,  Edward N. Van Den Brink

IPC: C07K16/28 ,  C07K16/32 ,  A61K39/00

Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

公开(公告)号：US10906991B2

公开(公告)日：2021-02-02

申请号：US14934956

申请日：2015-11-06

Applicant: GENMAB A/S

Inventor： Janine Schuurman ,  Tom Vink ,  Jan Van De Winkel ,  Aran Frank Labrijn ,  Rob Aalberse ,  Marijn Van Der Neut Kolfschote ,  Paul Parren

IPC: C07K16/46 ,  C07K16/00 ,  C07K16/28

Abstract: The invention relates to an ex vivo method for the generation of a bispecific antibody, comprising the steps of: a) providing a first antibody having a first binding specificity, wherein said first antibody comprises an IgG4-like CH3 region, b) providing a second antibody having a second binding specificity which differs from said first binding specificity, wherein said second antibody comprises an IgG4-like CH3 region, c) incubating said first and second antibodies together under reducing conditions which allow the cysteines in the core hinge region to undergo disulfide-bond isomerization, and d) obtaining a bispecific antibody. The invention furthermore relates to bispecific antibodies obtainable by the method of the invention.

公开(公告)号：US10457735B2

公开(公告)日：2019-10-29

申请号：US15538419

申请日：2016-01-08

Applicant: BIONTECH AG ,  GENMAB A/S

Inventor： Ugur Sahin ,  Friederike Gieseke ,  Isil Altintas ,  David Satijn ,  Paul Parren

IPC: C07K16/28

Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.

公开(公告)号：US20190169311A1

公开(公告)日：2019-06-06

申请号：US15998816

申请日：2018-08-16

Applicant: Genmab A/S

Inventor： Sandra Verploegen ,  David P.E. Satijn ,  Rene M.A. Hoet ,  Paul Parren ,  Jan Van De Winkel ,  Vibeke Miller Breinholt ,  Eva Ehrnrooth ,  Ole Baadsgaard ,  Tom Vink ,  Willem Karel Bleeker ,  Mischa Houtkamp ,  Maroeska Oudshoorn ,  Rob N. De Jong

IPC: C07K16/36 ,  A61K39/395

Abstract: Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.